Murphy Hentemann

Murphy Hentemann, PhD, joined Foghorn in 2018 as head of Program Management, now VP, Program Leadership. He brings more than 18 years of drug discovery experience to the organization.

Before joining Foghorn, Murphy was a Director of Oncology Program Management at Novartis Institute for Biomedical Research. Prior to that, he held positions of increasing responsibility at AstraZeneca, Array Biopharma, and Bayer Healthcare, as a medicinal chemist and drug discovery program leader. Murphy has contributed to the discovery and early development of multiple clinical candidates in the oncology space, including leading the teams that discovered ALIQOPA™ and Ipatasertib.

Murphy received a PhD in Organic Chemistry from Purdue University under the direction of Philip Fuchs, and then completed postdoctoral training at Memorial Sloan Kettering under Samuel Danishefsky as an NIH Postdoctoral Fellow.